FIG 5.

Efficacy of prophylactic anti-VEEV TcPAb treatment against high-dose aerosol challenge. Six-week-old BALB/c mice were treated with 100 μg of either the control TcPAb or the indicated anti-VEEV TcPAb followed by a high-dose aerosol (>100 LD₅₀) challenge with V3000 nluc TaV. Two doses of TcPAb were administered either i.p. (B to D) or i.p./i.n. (E to G), with the first dose 12 h before challenge and the second dose 48 h after challenge. Four to eight mice from the control or prophylactic groups were imaged by IVIS analysis at 5 days postchallenge, and photon flux was quantitated for the head (H). One mouse exhibiting the fewest clinical infection signs and one mouse exhibiting the greatest number and severity of clinical infection signs are shown in IVIS images from the control (A) or prophylactic (B to G) groups. All IVIS images are set to the same scale. Daily weights are shown for mice that received the negative-control TcPAb (black lines) (B to G) or prophylactic (colored lines) (B to G) treatments. *, P < 0.05 compared to the negative-control TcPAb as determined by Student's t test.